Biotech startups that raised Series A in the United Kingdom
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Bioliberty | Edinburgh | Series A | $3.3M | 2026-11-02 |
| Alchemab Therapeutics | London | Series A | $33.6M | 2026-07-09 |
| Apoha | London | Series A | $36.0M | 2026-06-03 |
| Lucida Medical | Cambridge | Series A | $11.5M | 2026-03-30 |
| KluraLabs | Haverhill | Series A | $11.0M | 2026-02-03 |
| EpilepsyGTx | Canterbury | Series A | $33.0M | 2025-12-10 |
| Verdiva Bio | London | Series A | $411.0M | 2025-01-09 |
| OxCan | Oxford | Series A | $11.0M | 2025-01-09 |
8 rows of the CSV in 5 of its 18 columns.
- The 125 biotech startups in the United Kingdom whose last round is Series A have raised $2.6B in total.
- 19 of them closed their most recent round in the last 12 months, $712.1M combined.
- The largest of those rounds is RQ Bio's $112.5M Series A, dated June 2026.
- The most recent is Alethio Therapeutics' $90.0M Series A on 5 November 2026.
- Innovate UK is an investor in 5 of them, more than any other fund.
- Health care is the most common other sector, with 91 companies (73%).
- 26% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (63% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
14 of 125| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Bioliberty | Bioliberty develops rehabilitation solutions for degenerative and traumatic conditions as a medtech start-up. | Biotech | Edinburgh | Series A | $3.3M | 2026-11-02 | $17.4M | Innovate UK, Scottish Enterprise, Old College Capital +2 | 11 to 50 | 2020 |
| Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
| Apoha | Apoha is a start-up that has not yet publicly launched. | Biotech | London | Series A | $36.0M | 2026-06-03 | $36.0M | Plug and Play, Innovate UK, Intel Ignite +2 | 1 to 10 | 2021 |
| Lucida Medical | Lucida Medical develops software for cancer diagnosis using MRI and radiology imaging, particularly for prostate cancer. | Biotech | Cambridge | Series A | $11.5M | 2026-03-30 | $22.5M | Innovate UK, XTX Ventures, WDH Investments | 11 to 50 | 2019 |
| KluraLabs | KluraLabs manufactures products that use nanotechnology to inactivate viruses and bacteria. | Biotech | Haverhill | Series A | $11.0M | 2026-02-03 | $11.0M | Starship Ventures | 11 to 50 | 2020 |
| EpilepsyGTx | EpilepsyGTx develops gene therapies to improve management of focal refractory epilepsy in late-stage clinical development. | Biotech | Canterbury | Series A | $33.0M | 2025-12-10 | $43.0M | UCL Technology Fund, HTH | 1 to 10 | 2021 |
| Verdiva Bio | Verdiva Bio develops treatments for patients with obesity and cardiometabolic diseases. | Biotech | London | Series A | $411.0M | 2025-01-09 | $411.0M | General Atlantic, RA Capital Management, OrbiMed +1 | 11 to 50 | 2024 |
| OxCan | OxCan develops machine learning and liquid biopsy tools for early lung cancer detection. | Biotech | Oxford | Series A | $11.0M | 2025-01-09 | $16.4M | Civilization Ventures, Eka Ventures, Oxford Technology Management +1 | 11 to 50 | 2020 |
| Solasta Bio | Solasta Bio develops environmentally friendly crop protection products. | Biotech | Glasgow | Series A | $14.0M | 2024-09-11 | Scottish Enterprise, Future Planet Capital, Forbion Capital Partners | 11 to 50 | 2020 | |
| Oxford Endovascular | Oxford Endovascular develops a novel treatment for brain aneurysms. | Biotech | Oxford | Series A | $10.2M | 2024-05-20 | $28.4M | Innovate UK, MedTech Innovator, Parkwalk Advisors +1 | 1 to 10 | 2015 |
| Curve Therapeutics | Curve Therapeutics develops a screening platform for drug discovery. | Biotech | Southampton | Series A | $51.4M | 2024-02-27 | Pfizer Venture Investments, British Patient Capital, Advent Life Sciences +2 | 11 to 50 | 2019 | |
| Mogrify | Mogrify develops in vivo reprogramming therapies for patients with degenerative diseases. | Biotech | Cambridge | Series A | $10.0M | 2023-10-02 | Parkwalk Advisors, 24 Haymarket, Ahren Innovation Capital | 11 to 50 | 2019 | |
| Sitryx Therapeutics | Sitryx Therapeutics develops disease-modifying therapeutics in immuno-oncology and immuno-inflammation. | Biotech | Oxford | Series A | $39.0M | 2023-09-27 | Sofinnova Partners, Oxford Science Enterprises, SV Health Investors +1 | 11 to 50 | 2018 | |
| YellowDog | YellowDog provides cloud native scheduling and provisioning technology that helps businesses scale their computing workloads. | Biotech | Bristol | Series A | $3.3M | 2019-03-27 | $7.0M | Bloc Ventures | 11 to 50 | 2015 |
Table 1. Biotech startups that raised Series A in the United Kingdom: the 14 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 125.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Apoha | Apoha is a start-up that has not yet publicly launched. | Biotech | London | Series A | $36.0M | 2026-06-03 | $36.0M | Plug and Play, Innovate UK, Intel Ignite +2 | 1 to 10 | 2021 |
| 2 | Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
| 3 | EpilepsyGTx | EpilepsyGTx develops gene therapies to improve management of focal refractory epilepsy in late-stage clinical development. | Biotech | Canterbury | Series A | $33.0M | 2025-12-10 | $43.0M | UCL Technology Fund, HTH | 1 to 10 | 2021 |
| 4 | Lucida Medical | Lucida Medical develops software for cancer diagnosis using MRI and radiology imaging, particularly for prostate cancer. | Biotech | Cambridge | Series A | $11.5M | 2026-03-30 | $22.5M | Innovate UK, XTX Ventures, WDH Investments | 11 to 50 | 2019 |
| 5 | KluraLabs | KluraLabs manufactures products that use nanotechnology to inactivate viruses and bacteria. | Biotech | Haverhill | Series A | $11.0M | 2026-02-03 | $11.0M | Starship Ventures | 11 to 50 | 2020 |
| 6 | Bioliberty | Bioliberty develops rehabilitation solutions for degenerative and traumatic conditions as a medtech start-up. | Biotech | Edinburgh | Series A | $3.3M | 2026-11-02 | $17.4M | Innovate UK, Scottish Enterprise, Old College Capital +2 | 11 to 50 | 2020 |
Table 2. Biotech startups that raised Series A in the United Kingdom: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 5 | 4% | 3 | Bioliberty, Apoha, Lucida Medical |
| 2 | Scottish Enterprise | Government investment office | Glasgow, United Kingdom | 3 | 2% | 1 | Bioliberty |
| 3 | Parkwalk Advisors | Venture capital firm | London, United Kingdom | 3 | 2% | ||
| 4 | SV Health Investors | Private equity firm | Boston, United States | 2 | 2% | 1 | Alchemab Therapeutics |
| 5 | RA Capital Management | Startup incubator | Boston, United States | 2 | 2% | 1 | Alchemab Therapeutics |
| 6 | Future Planet Capital | Venture capital firm | London, United Kingdom | 2 | 2% | ||
| 7 | Octopus Ventures | Venture capital firm | London, United Kingdom | 2 | 2% | ||
| 8 | Sofinnova Partners | Venture capital firm | Paris, France | 2 | 2% | ||
| 9 | Oxford Science Enterprises | Venture capital firm | Oxford, United Kingdom | 2 | 2% | ||
| 10 | IQ Capital | Venture capital firm | London, United Kingdom | 2 | 2% | ||
| 11 | Archangels | Angel group | Edinburgh, United Kingdom | 1 | 1% | 1 | Bioliberty |
| 12 | Eos | Venture capital firm | Saint Andrews, United Kingdom | 1 | 1% | 1 | Bioliberty |
| 13 | Old College Capital | University program | Edinburgh, United Kingdom | 1 | 1% | 1 | Bioliberty |
| 14 | DHVC | Venture capital firm | Palo Alto, United States | 1 | 1% | 1 | Alchemab Therapeutics |
| 15 | DCVC | Venture capital firm | Palo Alto, United States | 1 | 1% | 1 | Alchemab Therapeutics |
Table 3. Biotech startups that raised Series A in the United Kingdom: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 91 | 73% | $2.2B |
| Software | 14 | 11% | $223.4M |
| Hardware | 8 | 6% | $102.6M |
| Artificial intelligence | 4 | 3% | $157.9M |
| Fintech | 3 | 2% | $7.0M |
| Commerce | 1 | 1% | $11.0M |
| Energy | 1 | 1% | |
| Education | 1 | 1% | |
| Cybersecurity | 1 | 1% |
Table 4. Biotech startups that raised Series A in the United Kingdom by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 125 | 100% | $12.2M |
Table 5. Biotech startups that raised Series A in the United Kingdom by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| London | 43 | 34% |
| Cambridge | 19 | 15% |
| Oxford | 11 | 9% |
| Edinburgh | 6 | 5% |
| Manchester | 4 | 3% |
| Glasgow | 3 | 2% |
| Altrincham | 2 | 2% |
| Coventry | 2 | 2% |
| Bristol | 2 | 2% |
| Abingdon | 2 | 2% |
| Abingdon-on-thames | 1 | 1% |
| Harrow | 1 | 1% |
Table 6. Biotech startups that raised Series A in the United Kingdom by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 2 | 11% | $93.3M |
| October 2026 | 2 | 11% | $35.0M |
| September 2026 | 2 | 11% | $3.0M |
| July 2026 | 1 | 5% | $33.6M |
| June 2026 | 4 | 21% | $274.0M |
| May 2026 | 1 | 5% | $82.6M |
| March 2026 | 3 | 16% | $113.6M |
| February 2026 | 2 | 11% | $19.1M |
| January 2026 | 1 | 5% | $25.0M |
| December 2025 | 1 | 5% | $33.0M |
Table 7. Biotech startups that raised Series A in the United Kingdom: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 18 | 14% | $679.1M |
| 2025 | 12 | 10% | $852.0M |
| 2024 | 12 | 10% | $434.3M |
| 2023 | 16 | 13% | $347.3M |
| 2022 | 13 | 10% | $267.4M |
| 2021 | 9 | 7% | $170.5M |
Table 8. Biotech startups that raised Series A in the United Kingdom by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 6 | 5% |
| 2020 to 2022 | 26 | 21% |
| 2015 to 2019 | 50 | 40% |
| 2010 to 2014 | 27 | 22% |
| Before 2010 | 15 | 12% |
Table 9. Biotech startups that raised Series A in the United Kingdom by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 35 | 28% |
| 11 to 50 | 78 | 63% |
| 51 to 100 | 7 | 6% |
| 101 to 250 | 2 | 2% |
| 251 to 500 | 1 | 1% |
Table 10. Biotech startups that raised Series A in the United Kingdom by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in the United Kingdom. On 16 November 2026 that is 125 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 14 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 125 rows: 11 have no round amount, 0 no city and 33 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in the United Kingdom whose last round is Series A are on the list?
- 125, in the file dated 16 November 2026. 19 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 125 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.